Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Prostatic Diseases”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 181 records · Page 10Linked to original sources
PubMed2001

Pharmacologic agents in complementary medicine in prostatic disease.

The use of alternative medicine has increased considerably in the last 10 years. Some of the reasons for this trend include limited efficacy of existing treatments, perceived reduction in side effects with alternative treatments, patient's desire to maintain control over their treatment and a desire for a more "natural" treatment. The very high frequency of urologic diseases such as benign prostatic hyperplasia and prostate cancer makes these diseases natural targets of alternative medicine. Although a great number of therapeutic agents have been recommended for urologic diseases, this review examines the most promising for their use in benign prostatic hyperplasia and prostate cancer. (c) 2001 Prous Science. All rights reserved.

Journal Article↗
PubMed2004

Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem.

Dietary and supplemental zinc, especially in excess, has received much attention in numerous alternative medicine resources. There is a small amount of medical evidence that zinc may alleviate some mostly rare medical conditions (such as Wilson's disease). However, in prostate conditions, such as BPH, large concentrations of zinc are found in the prostate gland. Excess intake of zinc, especially with individual supplements, has the potential to encourage the growth of prostate conditions from BPH to cancer. In fact, one large study found a significantly higher risk of advanced prostate cancer in men consuming large intakes of these supplements. Large doses of zinc can inhibit the benefits of bisphosphonate drugs, increase testosterone level, increase cholesterol, reduce levels of "good cholesterol" or HDL, and can promote immune dysfunction. More research is needed in this area, but in the meantime, the time seems more than ripe to discourage or immediately discontinue the intake of larger concentrations of zinc for most individuals until adequate research resolves this controversial issue.

Dietary Supplements↗
PubMedDate not supplied

Ethnic differences in diet and associations with clinical markers of prostate disease in New Zealand men.

OBJECTIVE: To examine ethnic differences in diet and dietary associations with clinical markers of prostate disease in New Zealand men. MATERIALS AND METHODS: A total of 1031 males (616 New Zealand European, 230 Maori and 185 Pacific Islands) aged 40-69 years, with no history of prostate cancer, completed a questionnaire covering diet. A serum prostate specific antigen (PSA) blood analysis was also undertaken. Regression models were developed to examine the ethnic-specific levels of selected dietary components, and their relationship with PSA and urinary symptom scores. RESULTS: The results confirmed previously found ethnic differences in the New Zealand diet. Combined tomato intake was positively-correlated with free PSA and % free PSA (p=0.021, r=0.197 and p=0.011, r=0.096 respectively). Beer intake was negatively-correlated with total PSA (p=0.028, r=-0.071) and free PSA (p=0.004, r=-0.094). CONCLUSION: Ethnic differences found in the consumption of foods (associated with prostate cancer) highlight the possible importance of dietary interactions for ethnic prostate cancer risk. Associations between specific foods and PSA warrant further investigation.

Adult↗
PubMed1999

Use of symptom questionnaires in the assessment and follow-up of men with benign prostatic disease.

The assessment of lower urinary tract symptoms is an essential component of the evaluation of men with benign prostatic disease in clinical practice and research. Symptom evaluation is necessary for the formal evaluation of the effectiveness of treatments in randomized controlled trials and in the assessment of outcome in individuals, and can also be useful in determining the numbers of individuals in the community who might potentially require or benefit most from treatment. Increasingly, symptom assessments are being undertaken using a small number of questionnaires that are self-completed by patients and have been tested for validity and reliability.

Follow-Up Studies↗
PubMed1996

[Analysis of site differences in voiding condition of elderly men-- comparison to results of mass screening for prostate diseases between the villages of Shimamaki-mura, Hokkaido and Satomi-Mura, Ibaraki].

We performed mass screening for prostate diseases in the village of Satomi-mura, in Ibaraki Prefecture for males between 40 and 79 years old (participation rate; 21%). The findings were compared to those obtained by mass screening in the village of Shimamaki-mura, in Hokkaido Prefecture, conducted by the same examiners in a consistent manner (participation rate; 47%). When we considered the difference in biopsy rates between the two sites, the detection rate of prostate cancer in Satomi-mura was similar to that in Shimamaki-mura. There were no apparent differences in distribution of prostate volume, the International Prostate Symptom Score (I-PSS) and maximum flow rate between the two sites for each 10-year-age group. Our findings suggested that there was little site difference in the detection rate of prostate cancer and voiding condition between the two villages.

Adult↗
PubMed2004

Fingerprinting the diseased prostate: associations between BPH and prostate cancer.

Two of the most common diseases which occur in ageing men relate to their prostate. BPH and prostate cancer are prevalent diseases which have an impact on most men as they age. The advent of gene expression analysis has provided an opportunity to examine these diseases in a novel fashion. These analyses, to date, have revealed associations between these two diseases which have not been previously identified. These commonalities include global genetic changes which occur throughout the prostates in individuals with these diseases. Understanding the fingerprints of these diseases is providing novel markers and treatment strategies for both BPH and prostate cancer.

Androgens↗
PubMed1994

5 alpha-reductase inhibitors and prostatic disease.

5 alpha-Reductase inhibitors are a new class of substances with very specific effects on type I and type II 5 alpha R which may be of use in the treatment of skin disease, such as male pattern baldness, male acne and hirsutism, as well as prostatic hyperplasia and prostate cancer. At least two types of 5 alpha R inhibitors with a different pH optimum have been described. cDNA encoding for both the type I and the type II enzyme has been cloned. Most of the orally effective 5 alpha R inhibitors belong to the class of 4-azasteroids. The radical substituted in the 17 position of the steroid ring seems to be related to species specific variations and to the types of 5 alpha R enzymes in different species and organ systems. 5 alpha R inhibitors lead to a decrease of plasma DHT by about 65% while there is a slight rise in plasma testosterone. The decrease of tissue DHT in the ventral prostate of the intact rat, the dog and in humans is more pronounced and amounts to about 85%. There is a reciprocal rise of tissue T in these systems. The application of an inhibitor of 5 alpha R type II leads to a shrinkage of BPH in men by about 30%. In the rat a similar shrinkage accompanied by a significant decrease of total organ DNA occurs. This decrease, however, is not as pronounced as can be achieved with castration.(ABSTRACT TRUNCATED AT 250 WORDS)

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗
PubMed2000

Observations on EGFR gene amplification and polymorphism in prostatic diseases.

This study was designed to determine the amplification and polymorphism of epidermal growth factor receptor (EGFR) gene in prostatic diseases like benign hypertrophy (BPH) and carcinoma (CaP). The EGFR gene was found to be amplified in grade IV BPH as compared to grade II BPH. Digestion of genomic DNA with MspI and HpaII revealed the presence of a 5kb band following southern blot analysis. This 5kb band was present in all the CaP cases and in one out of three BPH cases. It is possible that such a polymorphism is associated with the type or extent of tumor progression.

Aged↗